Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
20 09 2021
Historique:
accepted: 19 08 2021
revised: 30 07 2021
received: 26 06 2021
pubmed: 22 8 2021
medline: 9 11 2021
entrez: 21 8 2021
Statut: ppublish

Résumé

The PS modification enhances the nuclease stability and protein binding properties of gapmer antisense oligonucleotides (ASOs) and is one of very few modifications that support RNaseH1 activity. We evaluated the effect of introducing stereorandom and chiral mesyl-phosphoramidate (MsPA) linkages in the DNA gap and flanks of gapmer PS ASOs and characterized the effect of these linkages on RNA-binding, nuclease stability, protein binding, pro-inflammatory profile, antisense activity and toxicity in cells and in mice. We show that all PS linkages in a gapmer ASO can be replaced with MsPA without compromising chemical stability and RNA binding affinity but these designs reduced activity. However, replacing up to 5 PS in the gap with MsPA was well tolerated and replacing specific PS linkages at appropriate locations was able to greatly reduce both immune stimulation and cytotoxicity. The improved nuclease stability of MsPA over PS translated to significant improvement in the duration of ASO action in mice which was comparable to that of enhanced stabilized siRNA designs. Our work highlights the combination of PS and MsPA linkages as a next generation chemical platform for identifying ASO drugs with improved potency and therapeutic index, reduced pro-inflammatory effects and extended duration of effect.

Identifiants

pubmed: 34417625
pii: 6355891
doi: 10.1093/nar/gkab718
pmc: PMC8450106
doi:

Substances chimiques

Mesylates 0
Oligonucleotides, Antisense 0
Phosphoramides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9026-9041

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Nucleic Acids Res. 2020 Jun 4;48(10):5235-5253
pubmed: 32356888
Drug Metab Dispos. 2007 Mar;35(3):460-8
pubmed: 17172312
Nat Biotechnol. 2019 Jun;37(6):640-650
pubmed: 31036929
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32370-32379
pubmed: 33288723
Mol Ther Nucleic Acids. 2017 Jun 16;7:20-30
pubmed: 28624195
J Am Chem Soc. 2020 Apr 22;142(16):7456-7468
pubmed: 32202774
Nucleic Acids Res. 2019 Feb 20;47(3):1110-1122
pubmed: 30566688
Cell Metab. 2018 Apr 3;27(4):714-739
pubmed: 29617640
Chem Commun (Camb). 2012 Aug 25;48(66):8195-7
pubmed: 22614180
J Am Chem Soc. 2020 Sep 2;142(35):14754-14771
pubmed: 32786803
DNA Repair (Amst). 2019 Dec;84:102672
pubmed: 31371183
J Clin Invest. 2019 Mar 1;129(3):915-925
pubmed: 30688661
Nucleic Acid Ther. 2021 Jun;31(3):190-200
pubmed: 33989066
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1229-1234
pubmed: 30622178
Nat Rev Drug Discov. 2021 Jun;20(6):427-453
pubmed: 33762737
J Am Chem Soc. 2008 Nov 26;130(47):16031-7
pubmed: 18980312
N Engl J Med. 2017 Apr 13;376(15):1430-1440
pubmed: 28306389
Biochem Pharmacol. 2021 Jul;189:114196
pubmed: 32800852
ACS Med Chem Lett. 2021 Apr 05;12(6):922-927
pubmed: 34141070
J Med Chem. 2016 Mar 24;59(6):2718-33
pubmed: 26914862
J Am Chem Soc. 2003 Jul 9;125(27):8307-17
pubmed: 12837103
Nucleic Acids Res. 2020 Dec 2;48(21):11827-11844
pubmed: 32808038
PLoS One. 2016 Aug 29;11(8):e0161930
pubmed: 27571227
J Pharmacol Exp Ther. 2005 Sep;314(3):972-9
pubmed: 15919763
Nucleic Acids Res. 2021 Feb 26;49(4):1828-1839
pubmed: 33544849
Nucleic Acids Res. 2015 Mar 11;43(5):2927-45
pubmed: 25712094
Nucleic Acids Res. 2019 Jun 20;47(11):5465-5479
pubmed: 31034558
J Org Chem. 2010 Mar 5;75(5):1569-81
pubmed: 20136157
Nucleic Acids Res. 1995 Dec 25;23(24):5000-5
pubmed: 8559657
J Biol Chem. 1999 Oct 1;274(40):28270-8
pubmed: 10497183
Nucleic Acid Ther. 2014 Dec;24(6):374-87
pubmed: 25353652
J Am Chem Soc. 2020 May 27;142(21):9661-9674
pubmed: 32374993
Nat Biotechnol. 2017 Mar;35(3):230-237
pubmed: 28244996

Auteurs

Brooke A Anderson (BA)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Graeme C Freestone (GC)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Audrey Low (A)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Cheryl L De-Hoyos (CL)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

William J Drury Iii (WJD)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Michael E Østergaard (ME)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Michael T Migawa (MT)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Michael Fazio (M)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

W Brad Wan (WB)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Andres Berdeja (A)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Eli Scandalis (E)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Sebastien A Burel (SA)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Timothy A Vickers (TA)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Stanley T Crooke (ST)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Eric E Swayze (EE)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Xuehai Liang (X)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Punit P Seth (PP)

Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH